Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis
Thrombosis and Haemostasis · 01.11.2023 · 123 (11) · 1072-1088
DOI: 10.1055/s-0043-1770100 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.11.2023. Verfasst von Zhe Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China. Hauptthemen laut MEDLINE: Venous Thrombosis, Venous Thromboembolism. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 90 Literaturangaben.
Abstract (Originalsprache)
Background
Direct oral anticoagulants (DOACs) are effective for the management of thromboembolic disorders. However, bleeding remains a major concern in cirrhotic patients receiving DOACs.
Methods
PubMed, EMBASE, and Cochrane Library databases were searched. The incidence of bleeding episodes in cirrhotic patients receiving DOACs was pooled. Odds ratios (ORs) were calculated to compare the incidence of bleeding episodes in cirrhotic patients who received DOACs versus those who received conventional anticoagulants and did not receive anticoagulants.
Results
Twenty-nine studies were included. All bleeding, major bleeding, fatal bleeding, gastrointestinal bleeding, and intracranial hemorrhage episodes were observed in 310/2,469, 100/1,388, 2/611, 166/1,886, and 5/1,147 cirrhotic patients receiving DOACs, respectively. Their pooled incidences were 13, 6, 0, 8, and 0%, respectively. They became higher in subgroup analyses of studies with advanced age, a longer treatment duration, and Child–Turcotte–Pugh class C. Compared with conventional anticoagulants, DOACs were associated with lower incidences of all bleeding (OR = 0.71, 95% confidence interval [CI] = 0.52–0.98) and major bleeding (OR = 0.55, 95% CI = 0.37–0.83) in cirrhotic patients, but not those of fatal bleeding (OR = 0.21, 95% CI = 0.04–1.28), gastrointestinal bleeding (OR = 0.78, 95% CI = 0.52–1.17), or intracranial hemorrhage (OR = 0.36, 95% CI = 0.12–1.12). The incidences of all bleeding (OR = 1.04, 95% CI = 0.22–4.79) and major bleeding (OR = 0.96, 95% CI = 0.26–3.61) did not significantly differ between cirrhotic patients with portal vein thrombosis (PVT) who received DOACs and those who did not receive anticoagulants.
Conclusion
DOACs carry a low risk of bleeding in liver cirrhosis. Age, treatment duration, and Child–Turcotte–Pugh class may be associated with bleeding in cirrhotic patients receiving DOACs. The risk of bleeding is not increased by DOACs in cirrhotic patients with PVT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
- Postgraduate College, China Medical University, Shenyang, China.
- Department of Medicine and Surgery, University of Insubria, Varese, Italy.
- Department of Internal Medicine, Botucatu Medical School, São Paulo State University (UNESP), São Paulo, Brazil.
Zitieren
APA
Li, Z., Xu, W., Wang, L., Chai, L., Ageno, W., Romeiro, F. G., Li, H., & Qi, X. (2023). Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Thrombosis and Haemostasis, 123(11), 1072-1088. https://doi.org/10.1055/s-0043-1770100
Vancouver
Li Z, Xu W, Wang L, Chai L, Ageno W, Romeiro FG, et al. Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis. Thrombosis and Haemostasis. 2023;123(11):1072-1088. doi:10.1055/s-0043-1770100
BibTeX
@article{Li2023,
author = {Li, Zhe and Xu, Wentao and Wang, Le and Chai, Lu and Ageno, Walter and Romeiro, Fernando Gomes and Li, Hongyu and Qi, Xingshun},
title = {Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis},
journal = {Thrombosis and Haemostasis},
year = {2023},
volume = {123},
number = {11},
pages = {1072--1088},
doi = {10.1055/s-0043-1770100}
}
EUVIMED